# Adebrelimab Infusion Plus Standard Care for Pancreatic Cancer With Pleural or Peritoneal Effusions

> **NCT07230301** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Sizhen Wang** · enrollment: 20 (estimated)

## Conditions studied

- Pancreatic Cancer Metastatic

## Interventions

- **DRUG:** Adebrelimab (PD-L1 inhibitor)

## Key facts

- **NCT ID:** NCT07230301
- **Lead sponsor:** Sizhen Wang
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-11-30
- **Primary completion:** 2027-06-30
- **Final completion:** 2028-06-30
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2025-11-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07230301

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07230301, "Adebrelimab Infusion Plus Standard Care for Pancreatic Cancer With Pleural or Peritoneal Effusions". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07230301. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*